Top

Published in:

01-03-2009 | Original Article

Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)

Authors: Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry M. Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew J. Monberg, Coleman K. Obasaju, Mark A. Socinski

Published in: Supportive Care in Cancer | Issue 3/2009

Abstract

Background

The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available—such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment.

Materials and methods

The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months.

Results

Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI = 52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining.

Conclusions

Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.

Ahrendt SA, Yang SC, Wu L et al (2002) Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg 123(3):466–473 discussion 473–464 doi:10.1067/mtc.2002.120343 PubMedCrossRef

Betticher DC, Hsu Schmitz SF, Totsch M et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94(8):1099–1106 doi:10.1038/sj.bjc.6603075 PubMedCrossRef

Bezjak A, Lee C, Ding K et al (2007) Quality of life (QOL) impact of adjuvant chemotherapy for early stage non-small cell lung cancer (NSCLC): final analysis of JBR.10 randomized trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:7585. (abstract)

Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11):1748–1756PubMed

Choong NW, Vokes EE (2005) Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 7(Suppl 3):S98–S104PubMedCrossRef

D’Cunha J, Corfits AL, Herndon JE 2nd et al (2002) Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer—preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 123(3):484–491 discussion 491 doi:10.1067/mtc.2002.119883 PubMedCrossRef

De Marinis F, Pereira J, Fossella F et al (2008) Lung cancer symptom scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small-cell lung cancer. J Thorac Oncol 3:30–36PubMedCrossRef

Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20(1):247–253 doi:10.1200/JCO.20.1.247 PubMedCrossRef

Detterbeck F, Socinski M, Gralla R et al (2008) Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small-cell lung cancer (NSCLC). J Thorac Oncol 3:37–45 doi:10.1097/JTO.0b013e31815e5d9a PubMedCrossRef

10.

Gatzemeier U, Shepherd FA, Le Chevalier T et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A(2):243–248 doi:10.1016/0959-8049(95)00444-0 PubMedCrossRef

11.

Gefitinib in treating patients who are undergoing surgery for stage I (2007) stage II, or stage iii non-small cell. Lung Cancer (June):7. http://www.cancer.gov/clinicaltrials/MCC-13922

12.

Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR (2002) Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77(4):371–383PubMedCrossRef

13.

Hollen PJ, Gralla RJ, Kris MG, Potanovich LM (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(Suppl 1):S51–S58 doi:10.1016/S0959-8049(05)80262-X PubMedCrossRef

14.

Hollen PJ, Gralla RJ, Kris MG et al (1994) Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73(8):2087–2098 doi:10.1002/1097-0142(19940415)73:8<2087::AID-CNCR2820730813>3.0.CO;2-XPubMedCrossRef

15.

Hollen PJ, Gralla RJ, Kris MG, Cox C (1994) Quality of life during clinical trials: conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2(4):213–222 doi:10.1007/BF00365725 PubMedCrossRef

16.

Hopwood P, Nankivell M, Pugh C, Gilligan D, Nicholson M, Stephens R (2007) Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25:9020 (abstract)

17.

Kenny PM, King MT, Viney RC et al (2008) Quality of life and survival in the 2 years after surgery for non-small-cell lung cancer. J Clin Oncol 26:233–241 doi:10.1200/JCO.2006.07.7230 PubMedCrossRef

18.

Manegold C, Bergman B, Chemaissani A et al (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8(6):525–529 doi:10.1023/A:1008207731111 PubMedCrossRef

19.

Martini N, Kris MG, Flehinger BJ et al (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55(6):1365–1373 discussion 1373–1364PubMedCrossRef

20.

Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41(5):582–592 doi:10.1097/00005650-200305000-00004 PubMedCrossRef

21.

Pantel K, Izbicki JR, Angstwurm M et al (1993) Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53(5):1027–1031PubMed

22.

Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K (1999) Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 68(6):2053–2058 doi:10.1016/S0003-4975(99)01125-X PubMedCrossRef

23.

Pisters KM, Ginsberg RJ, Giroux DJ et al (2000) Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119(3):429–439 doi:10.1016/S0022-5223(00)70120-6 PubMedCrossRef

24.

Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6):7–13 doi:10.1097/00001813-199512006-00002 PubMedCrossRef

25.

Rivera M, Detterbeck FC, Socinski MA et al (2005) Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer (NSCLC): initial results of pre-operative pulmonary function testing (PFTs) in the GINEST project. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23:7227 (abstract)

26.

Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26(1):7–14 doi:10.1016/S0169-5002(99)00045-8 PubMedCrossRef

27.

Roth JA, Atkinson EN, Fossella F et al (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21(1):1–6 doi:10.1016/S0169-5002(98)00046-4 PubMedCrossRef

28.

Takeda S, Maeda H, Okada T et al (2006) Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg 30(1):184–189 doi:10.1016/j.ejcts.2006.03.054 PubMedCrossRef

29.

Treat J, Belani C, Edelman M et al (2005) A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). Proc Am Soc Clin Oncol 23:7025 (abstract)

30.

van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM (2000) Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 117(2):374–379 doi:10.1378/chest.117.2.374 PubMedCrossRef

Title: Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
Authors: Richard J. Gralla
Martin J. Edelman
Frank C. Detterbeck
Thierry M. Jahan
David M. Loesch
Steven A. Limentani
Ramaswamy Govindan
Guangbin Peng
Matthew J. Monberg
Coleman K. Obasaju
Mark A. Socinski
Publication date: 01-03-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 3/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0489-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2009

The Efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following Carboplatin and Paclitaxel combination chemotherapy for non-small cell lung cancer

Life goals and purpose in life in cancer patients

Descriptive analysis of clinical factors affecting terminally ill cancer patients

Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence

The benefits of prayer on mood and well-being of breast cancer survivors

Age-specific correlates of quality of life in Chinese women with cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer